Australia Pharmaceutical Water Market By Type of Pharmaceutical Water (Water for Injection, Purified Water, Highly Purified Water, Sterile Water for Injection, Irrigation, Inhalation, Others); By Treatment Technology (Reverse Osmosis, Ultraviolet Disinfection, Distillation, Deionization, Others); By Application (Pharmaceutical & Biotechnology Manufacturing, Research Laboratories & Academic Institutes, Contract Manufacturing Organizations, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Australia Pharmaceutical Water Market size was valued at USD 389.54 million in 2018, grew to USD 779.59 million in 2024, and is anticipated to reach USD 1,736.49 million by 2032, expanding at a CAGR of 9.81% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Australia Pharmaceutical Water Market Size 2024
USD 779.59 Million
Australia Pharmaceutical Water Market, CAGR
9.81%
Australia Pharmaceutical Water Market Size 2032
USD 1,736.49 Million
The Australia Pharmaceutical Water Market is led by prominent players such as Veolia Water Technologies Australia, Ecolab Australia, Danaher Corporation Australia, SUEZ Water Technologies & Solutions Australia, Aquatec Maxcon, GEL Group, Trility, ClearWater Solutions Australia, GE Water & Process Technologies Australia, and Evoqua Water Technologies Australia. These companies strengthen their market positions through advanced purification technologies, automation, and compliance-focused solutions that meet TGA and GMP standards. Their emphasis on innovation, sustainability, and digital water management supports efficient operations across pharmaceutical and biotechnology facilities. New South Wales emerged as the leading region in 2024, capturing a 33% market share, driven by strong industrial concentration, robust infrastructure, and continuous investment in high-purity water systems for pharmaceutical production and research applications.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The Australia Pharmaceutical Water Market grew from USD 389.54 million in 2018 to USD 779.59 million in 2024 and is projected to reach USD 1,736.49 million by 2032, expanding at a CAGR of 9.81%.
Water for Injection (WFI) led the market in 2024 with a 42% share, driven by its essential role in sterile drug manufacturing and increasing biologics production.
Reverse Osmosis (RO) technology accounted for a 38% share due to its efficiency, reliability, and compliance with GMP standards in pharmaceutical purification processes.
Pharmaceutical & Biotechnology Manufacturing dominated applications with a 55% share, supported by expanding vaccine and injectable production facilities across Australia.
New South Wales led regionally with a 33% share in 2024, supported by strong pharmaceutical infrastructure, active R&D centers, and significant investment in advanced water purification systems.
Market Segment Insights
By Type of Pharmaceutical Water
Water for Injection (WFI) dominated the Australia Pharmaceutical Water Market in 2024 with a 42% share. The segment’s leadership stems from its critical use in parenteral drug manufacturing, sterile formulations, and biologics production. Strict quality standards by the TGA and growing demand for injectable medicines drive consistent investment in high-purity water systems. Rising biologics and vaccine production further strengthen WFI’s dominance in Australia’s pharmaceutical water infrastructure.
For instance, Pfizer Australia upgraded its Melbourne plant during 2024, integrating high-purity water loops designed to meet TGA-grade WFI standards for injectable drug production.
By Treatment Technology
Reverse Osmosis (RO) held the largest share of 38% in 2024 within the Australia Pharmaceutical Water Market. RO systems are favored for their cost efficiency, high contaminant removal rate, and compliance with GMP standards. Widespread adoption in both purified and WFI systems enhances their utility across pharmaceutical plants. The demand for low-maintenance and energy-efficient water purification systems continues to strengthen RO’s market position.
For instance, Veolia Water Technologies introduced its improved Orion RO system optimized for pharmaceutical-grade applications in Australia, offering enhanced energy recovery and membrane lifespan.
By Application
Pharmaceutical & Biotechnology Manufacturing accounted for a 55% share of the Australia Pharmaceutical Water Market in 2024. This segment leads due to the extensive need for purified and WFI-grade water in drug formulation, quality testing, and cleaning processes. Expansion of biologics, vaccines, and sterile injectables manufacturing boosts demand for advanced water systems. Rising R&D spending by pharmaceutical firms further sustains this segment’s dominance.
Key Growth Driver
Expanding Biopharmaceutical and Vaccine Production
Australia’s growing focus on biologics and vaccine manufacturing drives high demand for pharmaceutical-grade water. The expansion of domestic production facilities, especially after COVID-19, has increased the need for reliable Water for Injection (WFI) systems. Biopharmaceutical companies are investing in advanced purification technologies to meet stringent sterility standards. This surge in biologics manufacturing capacity continues to strengthen the country’s pharmaceutical water infrastructure and system upgrades.
For instance, HRS Heat Exchangers supplied advanced cooling heat exchanger technology to one of Australia’s largest pharmaceutical manufacturers, enhancing WFI system efficiency in biopharmaceutical production environments.
Regulatory Emphasis on Water Quality Compliance
Strict regulatory standards set by the Therapeutic Goods Administration (TGA) and adherence to GMP norms support market growth. Pharmaceutical manufacturers must ensure consistent water purity for drug formulation, cleaning, and quality control. This compliance requirement encourages adoption of advanced treatment technologies such as reverse osmosis and distillation. Continuous audits and rising regulatory scrutiny further push companies to modernize existing water systems and validation processes.
For instance, CSL Limited deployed an automated water quality monitoring system in its Broadmeadows site in late 2023 to meet GMP-compliant microbial control standards across its biopharmaceutical manufacturing lines.
Increasing Investments in Facility Modernization
Rising capital investments by domestic and multinational pharmaceutical firms are transforming production capabilities in Australia. Companies are upgrading old water treatment infrastructure with automated systems that ensure reliability and reduced operational risk. The integration of digital monitoring and predictive maintenance improves efficiency and minimizes downtime. These investments reflect a broader trend toward sustainable, compliant, and energy-efficient pharmaceutical water management solutions.
Key Trend & Opportunity
Adoption of Smart and Automated Water Systems
Automation and digitalization are reshaping pharmaceutical water operations in Australia. Smart systems that monitor conductivity, temperature, and microbial levels in real time help achieve consistent compliance. The integration of IoT and AI in water management allows predictive maintenance and reduced human error. This technological shift presents strong opportunities for suppliers offering intelligent control systems and cloud-based monitoring solutions.
For instance, Hunter Water in New South Wales began piloting 500 advanced digital water meters in December 2024, providing real-time consumption data refreshed every 30 minutes to enhance leak detection and water management.
Growing Demand for Sustainable Water Treatment Solutions
Sustainability is becoming a strategic focus in the Australian pharmaceutical sector. Companies are investing in eco-efficient systems that minimize water wastage and energy use. The adoption of closed-loop purification and energy recovery technologies supports green manufacturing initiatives. Growing pressure to meet environmental standards creates new opportunities for vendors developing low-impact, sustainable water treatment solutions.
For instance, Veolia installed an AnoxKaldnes® Moving Bed Biofilm Reactor system at AstraZeneca’s manufacturing site in Sweden, achieving 97% removal of total organic carbon and 99% phosphorus from wastewater.
Key Challenge
High Initial Capital and Maintenance Costs
The installation of advanced pharmaceutical water systems requires significant upfront investment and ongoing maintenance expenses. Many small and mid-sized manufacturers find it difficult to afford high-end purification setups. Costs related to validation, monitoring, and system upgrades further strain budgets. These financial barriers often delay modernization and limit adoption of advanced water treatment technologies.
Complex Regulatory and Validation Procedures
Compliance with TGA and international standards such as USP and EP involves complex documentation and testing. Continuous validation and system qualification processes increase administrative and operational load. Any deviation from required parameters can lead to production delays or penalties. Navigating these strict regulatory frameworks remains a persistent challenge for manufacturers in Australia.
Shortage of Skilled Technical Workforce
The pharmaceutical water industry in Australia faces a shortage of professionals trained in advanced purification technologies. Operation and maintenance of high-purity systems demand expertise in automation, microbiology, and validation protocols. Limited availability of skilled staff increases operational risks and maintenance errors. This workforce gap highlights the need for targeted technical training and capacity development in the sector.
Regional Analysis
New South Wales
New South Wales led the Australia Pharmaceutical Water Market in 2024 with a 33% share. The region’s dominance stems from a dense cluster of pharmaceutical and biotechnology manufacturing units across Sydney and nearby industrial zones. Strong government support for medical research and health innovation enhances infrastructure growth. Major production facilities rely on advanced water purification systems for compliance with GMP standards. Increasing expansion by multinational companies further boosts investment in high-purity water technologies. It remains the central hub for pharmaceutical production and regulatory compliance in Australia.
Victoria
Victoria accounted for a 28% share of the Australia Pharmaceutical Water Market in 2024. The state’s well-established pharmaceutical base in Melbourne drives significant adoption of Water for Injection (WFI) and purified water systems. Research institutions and academic laboratories contribute to continuous technological innovation in water treatment. Strong collaborations between public health agencies and private manufacturers promote capacity expansion. It continues to attract investments in sustainable and automated purification systems supporting advanced drug development.
Queensland
Queensland captured a 17% share in the Australia Pharmaceutical Water Market in 2024. Rapid growth in contract manufacturing organizations and medical research facilities strengthens the region’s demand for purified and sterile water systems. The Brisbane industrial corridor houses several production plants adopting digitalized water monitoring solutions. Government incentives for healthcare manufacturing promote infrastructure modernization. It shows steady expansion in pharmaceutical-grade water facilities aligned with environmental sustainability goals.
Western Australia
Western Australia held a 12% share in the Australia Pharmaceutical Water Market in 2024. The region’s growth is supported by increasing bioprocessing and sterile product manufacturing activities. Companies are upgrading treatment technologies to meet TGA quality requirements and ensure consistent purity. Water scarcity challenges encourage the use of energy-efficient purification systems. It benefits from rising investment in advanced utilities and pharmaceutical infrastructure.
South Australia and Others
South Australia, along with Tasmania and the Northern Territory, collectively accounted for a 10% share in 2024. The region’s pharmaceutical presence is smaller but steadily developing through niche manufacturing and research initiatives. New projects in medical devices and biopharma stimulate moderate demand for purified water systems. Collaboration between universities and technology suppliers fosters innovation in compact treatment units. It continues to witness gradual adoption of modern purification solutions to support local production and testing facilities.
Market Segmentations:
By Type of Pharmaceutical Water
Water for Injection (WFI)
Purified Water
Highly Purified Water
Sterile Water for Injection, Irrigation, Inhalation
Others
By Treatment Technology
Reverse Osmosis (RO)
Ultraviolet (UV) Disinfection
Distillation
Deionization
Others
By Application
Pharmaceutical & Biotechnology Manufacturing
Research Laboratories & Academic Institutes
Contract Manufacturing Organizations (CMOs)
Others
By Region
New South Wales
Victoria
Queensland
Western Australia
South Australia
Others
Competitive Landscape
The Australia Pharmaceutical Water Market features a moderately consolidated competitive landscape dominated by global and regional players specializing in advanced water treatment technologies. Leading companies such as Veolia Water Technologies Australia, Ecolab Australia, Danaher Corporation Australia, and SUEZ Water Technologies & Solutions Australia maintain strong market positions through extensive product portfolios, turnkey solutions, and regulatory compliance expertise. Local firms like Aquatec Maxcon, Trility, and GEL Group contribute through customized installations and efficient service networks. Competition centers on technology innovation, system reliability, and cost-effective maintenance contracts. Companies increasingly invest in automation, IoT-enabled monitoring, and energy-efficient purification systems to meet evolving TGA and GMP standards. Strategic partnerships with pharmaceutical manufacturers, combined with growing emphasis on sustainability and validation services, continue to shape the competitive environment. The market is expected to witness rising collaboration between technology providers and biopharma producers to ensure compliance, reduce operational costs, and enhance process water quality.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In July 2024, De.mem Limited completed the acquisition of Auswater Systems Pty Ltd.
In March 2025, Centurion acquired WestWater Enterprises (Australia) to expand its water treatment capabilities.
In August 2025, AxFlow acquired Advanced Pump Technologies Pty Ltd (APT Water) in Australia, gaining strength in fluid handling and filtration systems.
Report Coverage
The research report offers an in-depth analysis based on Type of Pharmaceutical Water, Treatment Technology, Application and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Demand for high-purity water systems will increase with expanding biologics and vaccine production.
Pharmaceutical companies will adopt automated monitoring to improve water quality control.
Energy-efficient and sustainable purification systems will gain wider acceptance.
Local manufacturers will upgrade infrastructure to meet stricter TGA and GMP standards.
Partnerships between global technology providers and domestic firms will strengthen market capability.
Investment in digital validation and real-time data tracking will improve compliance efficiency.
Growth of contract manufacturing organizations will boost demand for modular water systems.
Research institutes will drive innovation in compact and eco-friendly water treatment units.
Training programs will expand to address the shortage of skilled water system operators.
Increasing focus on sustainability will lead to adoption of closed-loop and low-waste purification models.
CHAPTER NO. 1: GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries CHAPTER NO. 2: EXECUTIVE LENS
2.1 Pulse of the Industry – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Million)
2.3. Premium Insights – Based on Primary Interviews CHAPTER NO. 3: PHARMACEUTICAL WATER MARKET FORCES & INDUSTRY PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
3.6 Price Trend Analysis
3.6.1 Country-wise Price Trend
3.6.2 Price Trend by Product CHAPTER NO. 4: KEY INVESTMENT EPICENTER
4.1 Country-wise Goldmines – High-Growth Geographies
4.2 Product Frontiers – Lucrative Product Categories
4.3 Application Sweet Spots – Emerging Demand Segments CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Country-wise Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Type of Pharmaceutical Water & Application Revenue CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS
6.1. Import Analysis by Country
6.1.1. Australia Pharmaceutical Water Import Revenue By Country
6.2. Export Analysis by Country
6.2.1. Australia Pharmaceutical Water Export Revenue By Country CHAPTER NO. 7: COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Australia Pharmaceutical Water: Company Market Share
7.2. Australia Pharmaceutical Water Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Product Launch
7.3.3. Country-wise Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024 CHAPTER NO. 8: PHARMACEUTICAL WATER MARKET – BY TYPE OF PHARMACEUTICAL WATER SEGMENT ANALYSIS
8.1. Pharmaceutical Water Overview by Type of Pharmaceutical Water Segment
8.1.1. Pharmaceutical Water Revenue Share By Type of Pharmaceutical Water
8.2. Water for Injection (WFI)
8.3. Purified Water
8.4. Highly Purified Water
8.5. Sterile Water for Injection, Irrigation, Inhalation
8.6. Others CHAPTER NO. 9: PHARMACEUTICAL WATER MARKET – BY TREATMENT TECHNOLOGY SEGMENT ANALYSIS
9.1. Pharmaceutical Water Overview by Treatment Technology Segment
9.1.1. Pharmaceutical Water Revenue Share By Treatment Technology
9.2. Reverse Osmosis (RO)
9.3. Ultraviolet (UV) Disinfection
9.4. Distillation
9.5. Deionization
9.6. Others CHAPTER NO. 10: PHARMACEUTICAL WATER MARKET – BY APPLICATION SEGMENT ANALYSIS
10.1. Pharmaceutical Water Overview by Application Segment
10.1.1. Pharmaceutical Water Revenue Share By Application
10.2. Pharmaceutical & Biotechnology Manufacturing
10.3. Research Laboratories & Academic Institutes
10.4. Contract Manufacturing Organizations (CMOs)
10.5. Others CHAPTER NO. 11: PHARMACEUTICAL WATER MARKET – COUNTRY-WISE ANALYSIS
11.1. Pharmaceutical Water Overview by Country Segment
11.1.1. Australia Pharmaceutical Water Revenue Share By Country
11.1.2. Country
11.1.3. Australia Pharmaceutical Water Revenue By Country
11.1.4. Type of Pharmaceutical Water
11.1.5. Australia Pharmaceutical Water Revenue By Type of Pharmaceutical Water
11.1.6. Treatment Technology
11.1.7. Australia Pharmaceutical Water Revenue By Treatment Technology
11.1.8. Application
11.1.9. Australia Pharmaceutical Water Revenue By Application CHAPTER NO. 12: COMPANY PROFILES
12.1. Veolia Water Technologies Australia
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.3. Financial Overview
12.1.4. Recent Developments
12.1.5. Growth Strategy
12.1.6. SWOT Analysis
12.2. Ecolab Australia
12.3. Danaher Corporation Australia
12.4. SUEZ Water Technologies & Solutions Australia
12.5. Aquatec Maxcon
12.6. GEL Group
12.7. Trility
12.8. ClearWater Solutions Australia
12.9. GE Water & Process Technologies Australia
12.10. Evoqua Water Technologies Australia
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions
Which Australia Pharmaceutical Water Market segment held the largest share in 2024?
The Water for Injection (WFI) segment dominated the Australia Pharmaceutical Water Market in 2024, capturing a 42% share due to its vital use in sterile drug manufacturing.
What are the primary factors fueling the growth of the Australia Pharmaceutical Water Market?
Key growth drivers include rising biologics production, strict TGA compliance standards, increased investment in facility modernization, and adoption of automated, energy-efficient purification systems.
Who are the leading companies in the Australia Pharmaceutical Water Market?
Major players include Veolia Water Technologies Australia, Ecolab Australia, Danaher Corporation Australia, SUEZ Water Technologies & Solutions Australia, Aquatec Maxcon, Trility, and GEL Group.
Which region commanded the largest share of the Australia Pharmaceutical Water Market in 2024?
New South Wales led the Australia Pharmaceutical Water Market in 2024 with a 33% share, supported by advanced manufacturing infrastructure and strong pharmaceutical industry presence.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Europe Pharmaceutical Water Market was valued at USD 4,290.41 million in 2018, grew to USD 7,235.40 million in 2024, and is anticipated to reach USD 14,105.75 million by 2032, expanding at a CAGR of 8.0% during the forecast period.
The North America Pharmaceutical Water Market was valued at USD 9,849.30 million in 2018, grew to USD 17,393.16 million in 2024, and is projected to reach USD 37,427.29 million by 2032, expanding at a CAGR of 9.4% during the forecast period.
Global Pharmaceutical Water Market size was valued at USD 23,162.04 million in 2018, grew to USD 41,343.44 million in 2024, and is anticipated to reach USD 88,711.39 million by 2032, expanding at a CAGR of 9.33% during the forecast period.
Japan Pharmaceutical Water Market size was valued at USD 819.04 million in 2018, grew to USD 1,672.74 million in 2024, and is anticipated to reach USD 3,843.83 million by 2032, expanding at a CAGR of 10.21% during the forecast period.
The UK Pharmaceutical Water Market was valued at USD 299.29 million in 2018, increased to USD 550.93 million in 2024, and is projected to reach USD 1,087.93 million by 2032, expanding at a CAGR of 8.27% during the forecast period.
The U.S. Pharmaceutical Water Market was valued at USD 5,673.65 million in 2018, increased to USD 11,018.40 million in 2024, and is projected to reach USD 23,471.03 million by 2032, expanding at a CAGR of 9.23% during the forecast period.
The Italy Pharmaceutical Water Market was valued at USD 460.92 million in 2018, grew to USD 817.32 million in 2024, and is projected to reach USD 1,534.50 million by 2032, expanding at a CAGR of 7.63% during the forecast period.
Germany Pharmaceutical Water Market size was valued at USD 658.32 million in 2018 to USD 1,223.46 million in 2024 and is anticipated to reach USD 2,448.13 million by 2032, at a CAGR of 8.44 % during the forecast period.
The France Pharmaceutical Water Market was valued at USD 728.61 million in 2018, grew to USD 1,310.01 million in 2024, and is projected to reach USD 2,505.44 million by 2032, expanding at a CAGR of 7.86% during the forecast period.
The Fabry Disease Therapeutic Market has witnessed steady growth in recent years and is expected to grow at a CAGR of 8.80% between 2024 and 2032. The market was valued at USD 1725.8 million in 2023 and is expected to reach USD 3686.8 million in 2032.
The Foot and Mouth Disease (FMD) Vaccines market size was valued at USD 2.68 billion in 2024 and is projected to reach USD 4.78 billion by 2032, growing at a CAGR of 7.5% during the forecast period.
The Idiopathic Pulmonary Fibrosis (IPF) Treatment market was valued at USD 3.25 billion in 2024 and is projected to reach USD 5.66 billion by 2032, expanding at a CAGR of 7.2% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$2999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
